In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Elevations in cardiac troponin (cTn) after long bouts of aerobic exercise are not associated with subclinical coronary artery ...

Outcomes in the observational study were better among patients treated by surgeons who regularly do ablations.

These data suggest that private equity-acquired hospitals are cherry-picking the healthiest patients as part of an effort to ...

Most cases are subclinical, but given the newness of the therapy, it’s necessary to keep tabs on the issue going forward.

The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.